Standard Optimization of Stem Cells in Parkinson's Disease and Atypical Parkinsonism

General Inclusion Criteria: * Participants aged 40-75 years old with a diagnosis of PD or PPS (DLB, PSP, MSA, CBD with parkinsonism) based upon clinical criteria and standardized testing * Participants time of documented PD or PPS is \</= 6 years * Participants with an anticipated survival of at least 3 years in the investigator's opinion * Participants who are willing and able to give informed consent * Participants who can comply with the study protocol over the 18-month duration * Stable medical profile for 60 days prior to the initial intake screening * Participants can ambulate at least 25m without assistance * No known history of heparin-induced thrombocytopenia PD Inclusion Criteria: * Idiopathic Parkinson's disease patients who meet the MDS's Clinical Diagnostic Criteria for Parkinson's disease * Responsive to levodopa or dopamine agonists defined by \>/= 33% improvement in "Off"/"On" symptoms by MDS-UPDRS-III * A modified Hoehn and Yahr stage of \</= 3 * Neuroimaging findings are consistent with PD and absent of atrophy or other brain pathology inconsistent with PD * "Normal" cognition as assessed by Montreal Cognitive Assessment (MoCA), with a value \>/= 26 PPS Inclusion Criteria: DLB - * High probability of cognitive capacity to give informed consent by the Montreal Cognitive Assessment (MoCA), with a value \>/= 23 * Probable DLB - DLB consortium: Two or more core clinical features are present (including features of parkinsonism for the study), or only one co…